DRT™ Platform

Proteostasis Therapeutics has assembled a Disease-Relevant Translation, DRT™ platform that combines genomics, proteomics, and functional assays with medicinal chemistry and systems biology to convert emerging knowledge of the Proteostasis Network (PN) and its function to discover novel therapeutics for diseases with huge unmet patient needs.

compound-progression

Proteostasis Therapeutics seeks to discover and develop a new class of drugs that regulate the PN. This approach integrates genomic, proteomic, and functional assay data to generate PN signatures that correlate with efficacy in a particular disease indication.
Data contained in these signatures are also used to characterize compound mechanism of action, optimize dosing regimens, and guide patient stratification. We are also continuing to apply the platform to identify and validate new targets arising from internal efforts as well as contributions by our collaborators as part of on-going relationships.

TECHNOLOGY